These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28350139)

  • 1. Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
    Lu AQ; Lv B; Qiu F; Wang XY; Cao XH
    Oncol Rep; 2017 Apr; 37(4):2071-2078. PubMed ID: 28350139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
    Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z
    Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H; Zhao L; Fang Q; Sun J; Zhang S; Zhan C; Liu S; Zhang Y
    PLoS One; 2014; 9(12):e115565. PubMed ID: 25531114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
    Fornari F; Pollutri D; Patrizi C; La Bella T; Marinelli S; Casadei Gardini A; Marisi G; Baron Toaldo M; Baglioni M; Salvatore V; Callegari E; Baldassarre M; Galassi M; Giovannini C; Cescon M; Ravaioli M; Negrini M; Bolondi L; Gramantieri L
    Clin Cancer Res; 2017 Jul; 23(14):3953-3965. PubMed ID: 28096271
    [No Abstract]   [Full Text] [Related]  

  • 7. ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells.
    Baik SH; Lee J; Lee YS; Jang JY; Kim CW
    Exp Mol Med; 2016 Mar; 48(3):e222. PubMed ID: 27012708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression.
    Azumi J; Tsubota T; Sakabe T; Shiota G
    Cancer Sci; 2016 Sep; 107(9):1256-62. PubMed ID: 27384977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.
    Liu K; Liu S; Zhang W; Jia B; Tan L; Jin Z; Liu Y
    Oncol Rep; 2015 Aug; 34(2):1003-10. PubMed ID: 26045065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
    Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells.
    Potenza N; Mosca N; Zappavigna S; Castiello F; Panella M; Ferri C; Vanacore D; Giordano A; Stiuso P; Caraglia M; Russo A
    J Cell Physiol; 2017 Jul; 232(7):1907-1913. PubMed ID: 27982429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
    Kabir TD; Ganda C; Brown RM; Beveridge DJ; Richardson KL; Chaturvedi V; Candy P; Epis M; Wintle L; Kalinowski F; Kopp C; Stuart LM; Yeoh GC; George J; Leedman PJ
    Hepatology; 2018 Jan; 67(1):216-231. PubMed ID: 28833396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma.
    Liu L; Lu L; Zheng A; Xie J; Xue Q; Wang F; Wang X; Zhou H; Tong X; Li Y; Zhu X; Wu G
    Oncotarget; 2017 Feb; 8(8):13666-13677. PubMed ID: 28099144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
    Xu J; Lin H; Li G; Sun Y; Chen J; Shi L; Cai X; Chang C
    EBioMedicine; 2016 Oct; 12():55-67. PubMed ID: 27688096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
    Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
    Wang H; Qian Z; Zhao H; Zhang X; Che S; Zhang H; Shang H; Bao J; Hao C; Liu J; Li Z
    Mol Med Rep; 2015 Sep; 12(3):3902-3908. PubMed ID: 26035694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.
    Emma MR; Iovanna JL; Bachvarov D; Puleio R; Loria GR; Augello G; Candido S; Libra M; Gulino A; Cancila V; McCubrey JA; Montalto G; Cervello M
    Cell Death Dis; 2016 Jun; 7(6):e2269. PubMed ID: 27336713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.
    Salvi A; Conde I; Abeni E; Arici B; Grossi I; Specchia C; Portolani N; Barlati S; De Petro G
    Mol Cancer; 2013 Dec; 12():162. PubMed ID: 24330766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.